GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations.

Li Q, Singh A, Hu R, Huang W, Shapiro DD, Abel EJ, Zong Y · 2026 · Virchows Archiv · Atlas ID LI2026

What this study shows

GPR143 is a sensitive and specific immunohistochemical biomarker for renal tumors driven by FLCN/TSC/MTOR-TFE pathway alterations, offering a practical diagnostic tool beyond existing ancillary tests.

Abstract

ShowHide

Diagnosis of MiT/TFE family translocation renal cell carcinoma is challenging. This study identifies GPR143 as a novel immunohistochemical marker that reliably identifies renal tumors harboring FLCN/TSC/mTOR-TFE pathway alterations, offering a practical diagnostic aid.

Read the full abstract on PubMed →

At a glance

Evidence type	M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Human tissue (renal tumor specimens)) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is.
Study type	5 - Mechanistic / In Vitro
Model system	Human tissue (renal tumor specimens)
Journal	Virchows Archiv
Year	2026
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1007/s00428-026-04646-4 · PMID 42463886

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	GPR143 immunohistochemistry
Target	MTOR / FLCN / TSC pathway in renal cell carcinoma
Model	Human
Effect	GPR143 overexpression identifies mTOR-pathway-driven renal tumors; positive diagnostic marker

In the Atlas

Cite this paper

ShowHide

Li, Q., Singh, A., Hu, R., Huang, W., Shapiro, D. D., Abel, E. J., & Zong, Y. (2026). GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations. Virchows Archiv. https://doi.org/10.1007/s00428-026-04646-4

@article{LI2026,
  author       = {Li, Q. and Singh, A. and Hu, R. and Huang, W. and Shapiro, D. D. and Abel, E. J. and Zong, Y.},
  title        = {{GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations}},
  journal      = {Virchows Archiv},
  year         = {2026},
  doi          = {10.1007/s00428-026-04646-4},
  note         = {PMID: 42463886},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record LI2026) [Data set]. https://mtor-atlas.org/study/LI2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_LI2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record LI2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/LI2026/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?